JP2018508208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508208A5 JP2018508208A5 JP2017543737A JP2017543737A JP2018508208A5 JP 2018508208 A5 JP2018508208 A5 JP 2018508208A5 JP 2017543737 A JP2017543737 A JP 2017543737A JP 2017543737 A JP2017543737 A JP 2017543737A JP 2018508208 A5 JP2018508208 A5 JP 2018508208A5
- Authority
- JP
- Japan
- Prior art keywords
- antibodies
- isolated
- recombinant
- agents
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021194395A JP2022058341A (ja) | 2015-02-17 | 2021-11-30 | クレブシエラ・ニューモニエのガラクタンベースのｏ抗原をターゲティングする抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15155448 | 2015-02-17 | ||
| EP15155448.2 | 2015-02-17 | ||
| PCT/EP2015/075583 WO2016131503A1 (en) | 2015-02-17 | 2015-11-03 | Antibodies targeting a galactan-based o-antigen of k. pneumoniae |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021194395A Division JP2022058341A (ja) | 2015-02-17 | 2021-11-30 | クレブシエラ・ニューモニエのガラクタンベースのｏ抗原をターゲティングする抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508208A JP2018508208A (ja) | 2018-03-29 |
| JP2018508208A5 true JP2018508208A5 (enExample) | 2019-04-18 |
| JP6987638B2 JP6987638B2 (ja) | 2022-01-05 |
Family
ID=52469764
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543737A Expired - Fee Related JP6987638B2 (ja) | 2015-02-17 | 2015-11-03 | クレブシエラ・ニューモニエのガラクタンベースのｏ抗原をターゲティングする抗体 |
| JP2021194395A Withdrawn JP2022058341A (ja) | 2015-02-17 | 2021-11-30 | クレブシエラ・ニューモニエのガラクタンベースのｏ抗原をターゲティングする抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021194395A Withdrawn JP2022058341A (ja) | 2015-02-17 | 2021-11-30 | クレブシエラ・ニューモニエのガラクタンベースのｏ抗原をターゲティングする抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11466074B2 (enExample) |
| EP (1) | EP3259287A1 (enExample) |
| JP (2) | JP6987638B2 (enExample) |
| KR (1) | KR20170122726A (enExample) |
| CN (1) | CN107371365B (enExample) |
| AU (1) | AU2015383632B2 (enExample) |
| BR (1) | BR112017017553A2 (enExample) |
| CA (1) | CA2973134A1 (enExample) |
| IL (1) | IL253920B2 (enExample) |
| MX (1) | MX2017009955A (enExample) |
| RU (2) | RU2021131224A (enExample) |
| WO (1) | WO2016131503A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2973134A1 (en) * | 2015-02-17 | 2016-08-25 | Arsanis Biosciences Gmbh | Antibodies targeting a galactan-based o-antigen of k. pneumoniae |
| AU2017306709A1 (en) | 2016-08-05 | 2019-03-14 | Humabs, BioMed SA | Anti-o2 antibodies and uses thereof |
| SG11201903063UA (en) * | 2016-10-19 | 2019-05-30 | Medimmune Llc | Anti-o1 antibodies and uses thereof |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| CN116033922B (zh) * | 2021-08-25 | 2025-08-19 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别肺炎克雷伯菌o1抗原的抗体及其应用 |
| US20250066458A1 (en) | 2021-12-06 | 2025-02-27 | Beijing Solobio Genetechnology Co., Ltd. | Bispecific Antibodies Specifically Binding to Klebsiella Pneumoniae O2 Antigen and O1 Antigen and Compositions Thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US20050112141A1 (en) * | 2000-08-30 | 2005-05-26 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| EP1311530A4 (en) | 2000-08-03 | 2004-10-06 | Wim-Van Schooten | PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| EP3124497B1 (en) | 2007-09-14 | 2020-04-15 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| KR102024922B1 (ko) | 2010-07-16 | 2019-09-25 | 아디맵 엘엘씨 | 항체 라이브러리 |
| CA2973134A1 (en) * | 2015-02-17 | 2016-08-25 | Arsanis Biosciences Gmbh | Antibodies targeting a galactan-based o-antigen of k. pneumoniae |
-
2015
- 2015-11-03 CA CA2973134A patent/CA2973134A1/en active Pending
- 2015-11-03 EP EP15790526.6A patent/EP3259287A1/en not_active Withdrawn
- 2015-11-03 MX MX2017009955A patent/MX2017009955A/es unknown
- 2015-11-03 AU AU2015383632A patent/AU2015383632B2/en not_active Ceased
- 2015-11-03 RU RU2021131224A patent/RU2021131224A/ru unknown
- 2015-11-03 KR KR1020177021389A patent/KR20170122726A/ko not_active Abandoned
- 2015-11-03 WO PCT/EP2015/075583 patent/WO2016131503A1/en not_active Ceased
- 2015-11-03 BR BR112017017553A patent/BR112017017553A2/pt not_active Application Discontinuation
- 2015-11-03 CN CN201580075698.6A patent/CN107371365B/zh not_active Expired - Fee Related
- 2015-11-03 RU RU2017132168A patent/RU2759950C2/ru active
- 2015-11-03 JP JP2017543737A patent/JP6987638B2/ja not_active Expired - Fee Related
- 2015-11-03 US US15/551,813 patent/US11466074B2/en active Active
-
2017
- 2017-08-09 IL IL253920A patent/IL253920B2/en unknown
-
2021
- 2021-11-30 JP JP2021194395A patent/JP2022058341A/ja not_active Withdrawn
-
2022
- 2022-08-16 US US17/820,082 patent/US20230220055A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2341461T5 (es) | Procedimientos de tratamiento de la artrosis con anticuerpos ANTI-IL-6 | |
| US10233234B2 (en) | Binding moieties for biofilm remediation | |
| US20240000971A1 (en) | Compositions and methods for the treatment of tauopathy | |
| US11098108B2 (en) | Antibody binding active alpha-synuclein | |
| BR112021003410A2 (pt) | anticorpos de domínio único anti-bcma, grupo de genes dos ditos anticorpos, polipeptídeo, vetor de expressão, célula hospedeira, receptor de antígeno quimérico, célula t modificada pelo mesmo, composição farmacêutica e usos dos ditos anticorpos | |
| UA119320C2 (uk) | Активуюча т-клітини біспецифічна антигензв'язувальна молекула | |
| Miersch et al. | Intracellular targeting with engineered proteins | |
| TWI859623B (zh) | Il10單體融合蛋白及其應用 | |
| Olga et al. | Nanobodies are potential therapeutic agents for the Ebola virus infection | |
| HK1259325A1 (zh) | 淀粉样蛋白β中的N-末端表位及其构象选择性抗体 | |
| TW202126684A (zh) | 抗α-溶血素的抗體及其應用 | |
| CN109414426A (zh) | 使用精氨酸耗竭剂的组合癌症免疫疗法 | |
| JP2019524851A (ja) | がんを治療するための組み合わせ | |
| KR20250004742A (ko) | 자궁내막증 및 다른 양성 부인과 신생물의 치료를 위한 제제 | |
| Wang et al. | The preparation and therapeutic roles of scFv-Fc antibody against Staphylococcus aureus infection to control bovine mastitis | |
| US9683042B2 (en) | T-cell-specific humanized single fragment antibody delivery vehicle | |
| Li et al. | Canine distemper virus (CDV)-neutralizing activities of an anti-CDV canine-derived single-chain variable antibody fragment 4-15 (scFv 4-15) screened by phage display technology | |
| US20200330591A1 (en) | Treatment | |
| JP2007023030A (ja) | 肝線維症を治療するための新しい組合せ | |
| AU2015258996A1 (en) | Diagnostic test and treatment/prevention of alzheimer's disease | |
| JP2020501518A (ja) | キメラタンパク質を用いたアレルギー疾患の治療 | |
| WO2025119317A1 (zh) | 一种抗犬pd-1抗体及其用途 | |
| JP6479331B2 (ja) | 脊髄組織標的化ペプチド及びその利用 | |
| WO2024020236A2 (en) | Monoclonal antibodies that interfere with iron uptake | |
| US20230391861A1 (en) | Potent binding agents for activation of the hedgehog signaling pathway |